Related Experiment Video
Updated: Apr 3, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth
Michal Hameiri-Grossman1,2, Adi Porat-Klein1,2, Isaac Yaniv1,3,2
1Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel.
Abstract:
Ewing Sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. microRNAs (miRNAs) are involved in cancer as tumor suppressors or oncogenes. We studied the involvement of miRNAs located on chromosomes 11q and 22q that participate in the most common translocation in ES. Of these, we focused on 3 that belong to the let-7 family.We studied the expression levels of let-7a, and let-7b and detected a significant correlation between low expression of let-7b and increased risk of relapse. let-7 is known to be a negative regulator of the RAS oncogene. Indeed, we detected an inverse association between the expression of let-7 and RAS protein levels and its downstream target p-ERK, following transfection of let-7 mimics and inhibitors. Furthermore, we identified let-7 as a negative regulator of HIF-1α and EWS-FLI-1. Moreover, we were able to show that HIF-1α directly binds to the EWS-FLI-1 promoter. Salirasib treatment in-vitro resulted in the reduction of cell viability, migration ability, and in the decrease of cells in S-phase. A significant reduction in tumor burden and in the expression levels of both HIF-1α and EWS-FLI-1 proteins were observed in mice after treatment.Our results support the hypothesis that let-7 is a tumor suppressor that negatively regulates RAS, also in ES, and that HIF-1α may contribute to the aggressive metastatic behavior of ES. Moreover, the reduction in the tumor burden in a mouse model of ES following Salirasib treatment, suggests therapeutic potential for this RAS inhibitor in ES.
Insights
let-7 microRNAs act as tumor suppressors in Ewing Sarcoma (ES) by regulating RAS and HIF-1α. Lower let-7b expression correlates with relapse risk, and Salirasib treatment reduced tumor burden in mice.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ewing Sarcoma (ES) is a prevalent pediatric bone cancer.
- MicroRNAs (miRNAs) play crucial roles in oncogenesis, acting as tumor suppressors or oncogenes.
- Specific miRNAs on chromosomes 11q and 22q are implicated in the common ES translocation.
Purpose of the Study:
- Investigate the role of let-7 family miRNAs in Ewing Sarcoma.
- Determine the correlation between let-7 expression and ES relapse risk.
- Elucidate the regulatory mechanisms of let-7 in ES, including its targets RAS, HIF-1α, and EWS-FLI-1.
Main Methods:
- Expression analysis of let-7a and let-7b in ES.
- In vitro studies using let-7 mimics and inhibitors to assess effects on RAS, p-ERK, HIF-1α, and EWS-FLI-1.
- In vitro and in vivo studies using Salirasib (a RAS inhibitor).
- Analysis of HIF-1α binding to the EWS-FLI-1 promoter.
Main Results:
- Low let-7b expression significantly correlated with increased ES relapse risk.
- let-7 negatively regulates RAS, HIF-1α, and EWS-FLI-1 expression in ES.
- HIF-1α directly binds to the EWS-FLI-1 promoter.
- Salirasib treatment reduced ES cell viability, migration, and S-phase population in vitro.
- Salirasib treatment significantly reduced tumor burden and HIF-1α/EWS-FLI-1 protein levels in vivo.
Conclusions:
- let-7 functions as a tumor suppressor in ES, inhibiting RAS, HIF-1α, and EWS-FLI-1.
- HIF-1α may contribute to the metastatic potential of ES.
- RAS inhibition via Salirasib shows therapeutic promise for Ewing Sarcoma.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
lncRNA - Long Non-coding RNAs
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

